XERIS BIOPHARMA HOLDINGS, INC. Fair Value Adjustment of Warrants
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2025-06-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for the quarter ending 2025-03-31 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for fiscal 2025 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for fiscal 2024 was -$8.00K.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for fiscal 2023 was -$1.00K.
- XERIS BIOPHARMA HOLDINGS, INC. fair value adjustment of warrants for fiscal 2022 was -$1.76M, a 350.71% decline from fiscal 2021.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 10-K · filed 2026-03-02 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$1.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | -$1.00K derived: sum of 3 quarters · filed 2026-03-02 | -$1.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$1.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.00K derived: sum of 3 quarters · filed 2026-03-02 | -$4.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.00K derived: sum of 2 quarters · filed 2026-03-02 | -$4.00K derived: sum of 3 quarters · filed 2026-03-02 | -$8.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | -$3.00K derived: sum of 2 quarters · filed 2025-11-06 | -$7.00K 10-Q · filed 2025-11-06 | -$5.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$3.00K 10-Q · filed 2025-08-07 | -$7.00K 10-Q · filed 2025-08-07 | -$5.00K derived: sum of 3 quarters · filed 2026-03-02 | -$22.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$4.00K 10-Q · filed 2025-05-08 | -$2.00K derived: sum of 2 quarters · filed 2026-03-02 | -$19.00K derived: sum of 3 quarters · filed 2026-03-02 | -$5.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$15.00K derived: sum of 2 quarters · filed 2026-03-02 | -$1.00K derived: sum of 3 quarters · filed 2026-03-02 | -$1.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | -$17.00K 10-Q · filed 2024-11-08 | -$3.00K derived: sum of 2 quarters · filed 2024-11-08 | -$3.00K 10-Q · filed 2024-11-08 | -$17.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $14.00K 10-Q · filed 2024-08-08 | $14.00K 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | -$9.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | -$14.00K derived: sum of 2 quarters · filed 2025-03-06 | -$23.00K derived: sum of 3 quarters · filed 2025-03-06 | -$539.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$23.00K derived: sum of 2 quarters · filed 2025-03-06 | -$539.00K derived: sum of 3 quarters · filed 2025-03-06 | -$1.76M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$9.00K 10-Q · filed 2023-11-09 | -$525.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.75M 10-Q · filed 2023-11-09 | -$953.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$516.00K 10-Q · filed 2023-08-08 | -$1.74M 10-Q · filed 2023-08-08 | -$944.00K derived: sum of 3 quarters · filed 2024-03-06 | -$1.02M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$1.22M 10-Q · filed 2023-05-09 | -$428.00K derived: sum of 2 quarters · filed 2024-03-06 | -$509.00K derived: sum of 3 quarters · filed 2024-03-06 | -$499.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $793.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $712.00K derived: sum of 2 quarters · filed 2024-03-06 | $722.00K derived: sum of 3 quarters · filed 2024-03-06 | $702.00K 10-K · filed 2024-03-06 |
| 2021-09-30 | -$81.00K 10-Q · filed 2022-11-09 | -$71.00K derived: sum of 2 quarters · filed 2022-11-09 | -$91.00K 10-Q · filed 2022-11-09 | -$146.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $10.00K 10-Q · filed 2022-08-10 | -$10.00K 10-Q · filed 2022-08-10 | -$65.00K derived: sum of 3 quarters · filed 2022-08-10 | $95.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$20.00K 10-Q · filed 2022-05-11 | -$75.00K derived: sum of 2 quarters · filed 2022-05-11 | $85.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $105.00K derived: sum of 2 quarters · filed 2022-03-11 | $9.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $160.00K 10-Q · filed 2021-11-10 | $64.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |